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ABSTRACT
Background: Cardiovascular prognostic models guide treatment allocation and support clinical decisions.
Whether there are valid models for Latin American and Caribbean (LAC) populations is unknown.
Objective: This study sought to identify and critically appraise cardiovascular prognostic models developed,
tested, or recalibrated in LAC populations.
Methods: The systematic review followed the CHARMS (CHecklist for critical Appraisal and data extraction
for systematic Reviews of prediction Modelling Studies) framework (PROSPERO [International Prospective
Register of Systemic Reviews]: CRD42018096553). Reports were included if they followed a prospective
design and presented a multivariable prognostic model; reports were excluded if they studied symptomatic
individuals or patients. The following search engines were used: EMBASE, MEDLINE, Scopus, SciELO, and
LILACS. Risk of bias assessment was conducted with PROBAST (Prediction model Risk Of Bias
ASsessment Tool). No quantitative summary was conducted due to large heterogeneity.
Results: From 2,506 search results, 8 studies (N ¼ 130,482 participants) were included for qualitative
synthesis. We could not identify any cardiovascular prognostic model developed for LAC populations;
reviewed reports evaluated available models or conducted a recalibration analysis. Only 1 study included a
Caribbean population (Puerto Rico); 3 studies were retrieved from Chile; 2 from Argentina, Brazil,
Colombia, and Uruguay; and 1 from Mexico. Four studies included population-based samples, and the
other 4 included people afﬁliated to a health facility (e.g., prevention clinics). Most studied participants were
older than 50 years, and there were more women in 5 reports. The Framingham model was assessed 6 times,
and the American College of Cardiology/American Heart Association pooled equation was assessed twice.
Across the prognostic models assessed, calibration varied widely from one population to another, showing
great overestimation particularly in some subgroups (e.g., highest risk). Discrimination (e.g., C-statistic) was
acceptable for most models; for Framingham it ranged from 0.66 to 0.76. The American College of Cardi-
ology/American Heart Association pooled equation showed the best discrimination (0.78). That there were few
outcome events was the most important methodological limitation of the identiﬁed studies.
Conclusions: No cardiovascular prognostic models have been developed in LAC, hampering key evidence to
inform public health and clinical practice. Validation studies need to improve methodological issues.
Cardiovascular diseases are the leading cause of death
and disability, both globally and in Latin America and the
Caribbean (LAC) [1,2]. These trends can be improved
through different strategies, modifying the distribution of
risk factors in the population as a whole, that is, a
population-based prevention approach (e.g., sugar taxes),
and through an overall risk-based prevention approach
[3,4]. It has been argued that the latter is cost-effective and
maximizes resources allocation (e.g., treatment) to those
who most need them with minimal harm [5,6]. However,
risk-based prevention needs accurate prognostic tools to
identify the target population.
There is some evidence that available cardiovascular
risk prediction equations do not perform well in LAC [7],
where cardiovascular key risk factors such as diabetes
seem to have different strength of association with car-
diovascular events [8]. Therefore, it becomes necessary to
identify which available equations have undergone local
scrutiny and whether new local tools have been devel-
oped. Even though there have been efforts to summarize
cardiovascular prognostic models [9,10], they did not
include studies written in Spanish or search engines with
large LAC inﬂuence, hence reporting no results from LAC
[10].
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Therefore, whether available cardiovascular prognostic
models have been tested or a new model has been derived
in LAC, remains largely unknown. Consequently, we
conducted a systematic review to summarize and critically
appraise studies evaluating or generating prognostic
models for cardiovascular outcomes conducted in LAC. In
so doing, we provide a comprehensive list of available
prognostic models, their strengths and limitations, as well
as recommendations and identiﬁcation of research gaps to
be addressed to improve cardiovascular prevention in LAC.
METHODS
Study design
The protocol for this systematic review of the literature was
registered at PROSPERO (International Prospective Register
of Systematic Reviews) (CRD42018096553) [11]. This work
adheres to the PRISMA (Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses) guidelines (see the
PRISMA Checklist in the Online Appendix) and CHARMS
(CHecklist for critical Appraisal and data extraction for sys-
tematic Reviews of prediction Modelling Studies) framework
[12-14]. Following the CHARMS framework, we sought
prognostic models that predict the risk of having a cardio-
vascular (nonfatal and fatal) outcome in a pre-deﬁned period
of time to be used in the general population to guide pre-
vention or treatment recommendations (Table 1). We exclu-
sively focused on reports that included LAC populations.
Eligibility criteria
Inclusion criteria comprised the following: 1) The overall
study design had to be prospective; this included studies that
turned into prospective cohorts, even though they were not
originally designed as such. For example, a cross-sectional
survey/study in which participants were looked up in death/
hospital registries after some years. 2) The study reported a
multivariable (i.e., at least 2 variables or predictors) model to
predict the risk of developing a nonfatal and/or fatal cardio-
vascular event (e.g., stroke, myocardial infarction, and death)
in an individual of the general population. On the other hand,
exclusion criteria included the following: 1) the study popu-
lation targeted symptomatic (e.g., emergency care) or only
patients with speciﬁc pathologies (e.g., chronic kidney dis-
ease); and 2) the studypopulation targetedpeoplewho, by the
time of the baseline assessment, had already experienced a
cardiovascular outcome (e.g., stroke).
Information sources
On July 15, 2018, a systematic search of publications was
conducted using 5 search engines: Ovid (EMBASE and
MEDLINE), Scopus, SciELO and LILACS; the latter 2 are
LAC-speciﬁc. The search terms were based on a recent
systematic review, which only included EMBASE, MED-
LINE, and articles in English [10]. In addition, terms
regarding LAC countries were included (i.e., country
names). No additional ﬁlters (e.g., language or publication
year) were set. The list of search terms is presented in the
Online Appendix.
Search
Before titles and abstract screening, 2 reviewers (RMC-L
and NP-B) agreed on a standard approach. Two random
samples of 50 search results were selected for training
purposes. Reviewers screened these titles and abstracts and
the inter-rater agreement and kappa estimator were
computed, aiming for an inter-rater agreement of at least
90% (see “Training of reviewers” in the Online Appendix).
After this standardization process, the 2 reviewers (RMC-L
and NP-B) screened all titles and abstracts following the
pre-speciﬁed framework and selection criteria. Discrep-
ancies were solved by a third reviewer independently (CA-
F). After the title and abstract selection, full text of selected
reports was sought and analyzed by 2 reviewers (RMC-L
and CA-F) following the same above-mentioned selection
criteria; discrepancies were solved by consensus between
these reviewers. These selection processes—titles and ab-
stracts as well as full texts—were conducted using the
online tool Rayyan-a [15]. With the ﬁnal list of studies to
be included for qualitative synthesis, 2 reviewers (RMC-L
and CA-F) extracted relevant information in a pre-speciﬁed
form developed by the authors based on the CHARMS
framework [13,14]. Meta-analysis was not conducted
because of the large heterogeneity among studies. Results
were summarized qualitatively and relevant point estimates
(e.g., C-statistics) are presented.
Risk of bias
The PROBAST tool for risk of bias appraisal was used [16-
18]. This tool was applied by 1 reviewer (RMC-L). The
PROBAST (Prediction model Risk Of Bias ASsessment
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TABLE 1. Review framework according to the CHARMS checklist
Item Criterion
Prognostic or diagnostic Prognostic, i.e., future events.
Scope Prognostic models to inform clinicians (and general
population) about the risk of a person to develop a
nonfatal/fatal cardiovascular event in a pre-deﬁned
period.
Type of prediction models Prognostic models with and/or without external
validation.
Prediction target population General population, men and women.
Outcome of interest Any nonfatal or fatal cardiovascular event, including
myocardial infarction, stroke, or cardiovascular
death; these outcomes could have been studied
independently or as a composite endpoint.
Prediction period Any (e.g., 10 yrs).
Intended moment to apply
the prediction tool
Prognostic tool to be used in primary prevention to
assess cardiovascular risk and thus guide
prevention/treatment.
CHARMS, CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction
Modelling Studies.
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Tool) tool has been designed to assess risk of bias of
multivariate prognostic models in 4 domains: 1) partici-
pants; 2) predictors; 3) outcome; and 4) analysis. The
criteria within each domain have 5 possible answers: yes;
probably yes; probably no; no; and no information. A
positive answer suggests no risk of bias. The domains had
3 potential outcomes: low; high; or unclear risk of bias.
RESULTS
Study selection
The search retrieved 2,506 results. After removing dupli-
cates, 2,420 titles and abstracts were screened, and of these
2,403 were excluded. Of the 17 reports studied in detail, 8
reports (N ¼ 130,482 participants) were selected for
qualitative synthesis (see the “Extraction form” in the
Online Appendix). There was the same number of reports
and studies.
Study characteristics
Five of the 8 reports were published in Latin-American
journals [19-23], with 3 of them written in Spanish
[19,22,23]. The oldest report was published in 2001 [24]
and the newest ones in 2018 [20,25]. Six reports were
conducted in 1 country only [19,21-24,26], and there were
2 multicountry efforts including Argentina, Chile, and
Uruguay [20], as well as Argentina, Brazil, Chile, and
Colombia (Fig. 1) [25]. The country that has been mostly
included in this review was Chile (3 of 8) [19,20,25];
Argentina, Brazil, Colombia, and Uruguay were studied in
2 reports [20,22,23,25,26]; Puerto Rico [24] and Mexico
[21] were included in 1 report (Fig. 1). None of the
reviewed studies reported adherence to the TRIPOD
(Transparent Reporting of a Multivariable Prognostic
Model for Individual Prognosis or Diagnosis) statement.
Four studies collected baseline information in the
2000s [19,20,25,26], 3 in the 1990s [21-23], and 1 be-
tween 1965 and 1968 [24]. One-half of the selected studies
Puerto Rico
Uruguay
BrazilColombia
Chile
Mul-country Mul-country
Mexico
• Jimenez-Corona,
   2009: not reported
• Munoz, 2014:
Framingham=0.66
PROCAM=0.58
PROCAM (sex)=0.75
• Acevedo, 2017:
Framingham=0.60
ACC/AHA=0.78
• Joseph, 2018:
NL-IHRS=0.72
FC-IHRS=0.74
• Gulayin, 2018:
Framingham=0.72
CUORE=0.75
Globorisk=0.75
ACC/AHA=0.74
• Sandoya, 2009:
Framingham (men)=0.76
Framingham (women)=0.67
• Polenz, 2015:
CHAD2DS2VASc=0.62
• D’Angosno, 2001:
Framingham=0.72
FIGURE 1. Discrimination estimates for each prognostic model by country. Conﬁdence intervals, when reported, are
presented in Online Table 1. In Acevedo [19], the outcome was cardiovascular mortality (did not include nonfatal
events). Brown dots represent studies conducted with populations in 1 country alone, and orange dots are for mul-
ticountry studies. PROCAM is a prognostic model for men, the “PROCAM (sex)” indicates the adjusted model so that it
can be used for men and women. Figure template from http://yourfreetemplates.com (see “Details for preparation of
Figure 1” in the Online Appendix). ACC/AHA, American College of Cardiology/American Heart Association; CHA2DS2-
VASc, Congestive Heart Failure, Hypertension, Age 75 Years, Diabetes Mellitus, Prior Stroke or Transient Ischemic
Attack or Thromboembolism, Vascular Disease, Age 65 to 74 Years, Sex; CUORE, Continuous Ultraﬁltration for
Congestive Heart Failure; FC-IHRS, fasting cholesterol INTERHEART risk score; INTERHEART, Effect of Potentially
Modiﬁable Risk Factors Associated With Myocardial Infarction in 52 Countries; NL-IHRS, nonlaboratory INTERHEART risk
score; PROCAM, Prospective Cardiovascular Münster.
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included population-based samples [20,21,24,25], whereas
the other one-half included people that were somehow
afﬁliated with health care facilities [19,22,23,26]. For
example, Muñoz et al. [22] included individuals who
attended a primary prevention clinic at the Central Military
Hospital in Colombia. Likewise, Acevedo et al. [19]
enrolled individuals who voluntarily attended a cardiol-
ogy prevention program in Chile. Women accounted for
more than one-half of the study population in 5 reports
[20-23,25]; in 1 report the women-to-men ratio was 1
[26]; and in 2 reports, men accounted for a larger share of
the study population [19,24]. Although it was not possible
to extract baseline age information from 1 study [20], the
others had either a mean of, or a larger proportion of,
people 50 years old [19,22-26]; in the report by Jimenez-
Corona et al. [21], the mean age was 47 years.
Across the studies summarized herein, the mean sample
size was 16,310 (SD: 37,107.4). Sample size was over 1,000
people in 7 of the studied reports, and 1 report included 468
individuals [26]. The largest sample sizes were from multi-
country endeavors [20,25]. The only study conducted in the
Caribbean in themid-1960s also had a large sample size (n¼
8,713) [24]. One study did not report follow-up time
duration [25], and another reported 10 years of follow-up or
censoring/event [22]; in general, follow-up time ranged from
12  4 months [26] to 9.2  2.1 years [23].
Most reports included the same outcomes as those of
the original prognostic model being studied (e.g., Fra-
mingham model); however, although the original model
included both nonfatal and fatal cardiovascular events, 1
report could only analyze the latter [19]. All reports
included the same predictors of the original model, and
these were assessed following standard procedures such as
clinical examination or laboratory tests. Further details
about the characteristics of the summarized reports,
including methods for predictors and outcomes ascertain-
ment, are shown in Table 2 and the Extraction Form in the
Online Appendix.
Cardiovascular prognostic models
Characteristics. None of the reviewed reports developed
a prognostic model for cardiovascular events based on LAC
populations; conversely, reviewed reports tested available
prognostic models [19,21-23,26] and some of them pur-
sued recalibration strategies [20,24,25].
The most frequently studied prognostic model was the
Framingham risk prediction equation (6 times) [19-24],
followed by the American College of Cardiology/American
Heart Association Pooled Cohorts Equation (2 times)
[19,20]; all other prognostic models were studied once: the
nonlaboratory INTERHEART (Effect of Potentially Modi-
ﬁable Risk Factors Associated With Myocardial Infarction
in 52 Countries) risk score and the fasting cholesterol
INTERHEART risk score [25]; Globorisk [20]; CUORE
(Continuous Ultraﬁltration for Congestive Heart Failure)
[20]; PROCAM (Prospective Cardiovascular Münster) [22];
and CHA2DS2VASc (Congestive Heart Failure, Hyperten-
sion, Age 75 Years, Diabetes Mellitus, Prior Stroke or
Transient Ischemic Attack or Thromboembolism, Vascular
Disease, Age 65 to 74 Years, Sex) [26].
Most reports studied prognostic models with few
outcome events per predictor. One study had 352 outcome
events [25], and in 6 reports this ﬁgure ranged from 15 [26]
to 72 [23] (Table 2). In addition, none reported a formal
sample size estimation or whether the number of outcome
events was adequate given the number of predictors.
Missing data was handled by conducting a complete-
case analysis in 5 reports [20,21,23,25,26], only 1 con-
ducted multiple imputation [22], and 2 did not provide
information about this matter [19,24]. Only 1 of the
reviewed reports conducted bootstrap analysis to compute
the conﬁdence intervals of the area under the receiver
operator curve [19].
Performance. Most reports provided estimates of cali-
bration and discrimination [20,22-25]; 2 also reported
classiﬁcation metrics such as positive/negative likelihood
ratio [20,26]. Calibration and discrimination estimates are
presented in Table 3 and Figure 1 (Online Table 1).
Although all discrimination estimates (e.g., C-statistics)
were reported with wide conﬁdence intervals, the highest
discrimination metric achieved was for the American Col-
lege of Cardiology/American Heart Association (ACC/AHA)
pooled risk equation by Acevedo et al. [19]; however, they
did not include all the outcomes of the original model so
that this estimate should be interpreted cautiously.
Risk of bias
In the participants, predictors, and outcome domains of
the risk of bias, all the reports were deemed to be of low
risk; the outcomes were clearly deﬁned and agreed with
those of the original model except for 1 study that
addressed the American College of Cardiology/American
Heart Association Pooled Cohorts Equation [19]. The
fourth criteria—analysis—was troublesome for the
reviewed reports largely because the few number of
outcome events, yielding a limited outcome-predictors
ratio, and for conducting complete-case analysis rather
than multiple imputation process. A summary of the risk of
bias analysis is shown in Table 4, and details on each cri-
terion across domains are provided in Risk of Bias (PRO-
BAST) in the Online Appendix.
DISCUSSION
Summary of evidence
Although cardiovascular prognostic models have been
summarized by global systematic reviews, none of them
found models or efforts undertaken in, and for, LAC
populations [9,10]. This work complements these reviews
with evidence from LAC and clearly demarcates that there
is scope for the improvement of cardiovascular risk pre-
diction in the LAC region. Eight studies were selected for
j gSCIENCE
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TABLE 2. Methodological characteristics of the reviewed prognostic models
Study,
Year (Ref. #) Predictors Ascertainment Outcome Details
Outcome
Ascertainment
Mean Follow-Up
(yrs)*
Baseline
Sample
Outcome
Events
Original
Prediction
Model Being
Tested
Polenz, 2015
[26]
Two physicians independently
performed clinical assessment
and reviewed electronic medical
records.
All-cause mortality,
stroke, transient
ischemic attack, acute
myocardial infarction,
and new atrial
ﬁbrillation/ﬂutter.
A specialist validated
each outcome
(e.g., stroke by a
neurologist).
1.3 (12  4
months)
468 15 CHA2DS2VASc
Muñoz, 2014
[22]
A researcher extracted all the
information from health records.
Total coronary disease:
coronary death;
myocardial infarction;
angina pectoris,
coronary insufﬁciency.
Hard coronary disease:
coronary death and
myocardial infarction.
By a researcher who
did not have
access to baseline
information.
Health records of
people suspected
to have had a
coronary event
were veriﬁed by
an internal
medicine
physician, who
deﬁned whether
these were either
total or hard
coronary diseases.
Cause of death
was based on
death certiﬁcates
or discharge
records.
10 yrs, event or
censoring
1,013 61 Framingham,
PROCAM
Gulayin, 2018
[20]
Blood pressure, measured after a 5-
min rest using a mercury or
aneroid sphygmomanometer;
average of 3 readings was used.
Blood samples were withdrawn
after 10 h of fasting.
Angina pectoris, nonfatal/
fatal myocardial
infarction, nonfatal/
fatal stroke, coronary
artery, carotid or
peripheral
revascularization,
heart failure, and
sudden death.
Events were
conﬁrmed by an
internal medicine
or cardiology
specialist after
veriﬁcation of the
event-speciﬁc
record.
Median ¼ 2.2
(IQR: 1.9e2.8)
6,364 60 CUORE,
Framingham,
Globorisk,
ACC/AHA
Pooled
Equation
(continued)
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TABLE 2. Continued
Study,
Year (Ref. #) Predictors Ascertainment Outcome Details
Outcome
Ascertainment
Mean Follow-Up
(yrs)*
Baseline
Sample
Outcome
Events
Original
Prediction
Model Being
Tested
Sandoya,
2009 [23]
Interviews for smoking and
medication use. Blood pressure
measured with a semi-automatic
validated instrument during a
resting period, using the mean of
3 measurements separated at
least 2 min. Blood samples were
withdrawn after a 12-h fasting
period and analyzed in a central
laboratory.
Ischemic disease as
ICD-10—I21, I20,
I20.9, I46—or
revascularization.
Based on discharge
diagnosis on
medical records,
when needed
telephone
communications
were held with
the participants or
relatives.
9.2  2.1 1,110 72 Framingham
Acevedo,
2017 [19]
Blood samples withdrawn after a 12-
h fasting period from venous
samples. All participants were
interviewed. Blood pressure was
measured according to JNC VII.
Nonfatal/fatal myocardial
infarction, nonfatal/
fatal stroke, or other
cardiovascular event.
Deaths registries were
obtained. No
information on
ascertainment of
nonfatal events; it
is reported that
the analyses were
based on
mortality as the
outcome
(cardiovascular
mortality).
7  3 3,284 34 ACC/AHA Pooled
Equation;
Framingham
and
Framingham
Chileno.
Jiménez-
Corona,
2009 [21]
Standard questionnaires were used.
Blood pressure was measured 3
times after a 5-min rest using a
random 0 sphygmomanometer;
the mean of the last 2 records
was used. Fasting serum total
cholesterol and HDL were
determined by cholesterol-
esterase.
Nonfatal/fatal myocardial
infarction.
By resting ECG or by
death certiﬁcate.
ECG were
interpreted
according to the
Minnesota code,
including possible
and probable
myocardial
infarctions. Death
certiﬁcates in
which the
underlying cause
of death was ICD-
10 410e410.9.
Median ¼ 6.2
(range
0.2e9.8)
1,667 58 Framingham by
Wilson et al.,
and by
Anderson
et al.
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Joseph, 2018
[25]
No details provided. Cardiovascular death,
myocardial infarction,
stroke, heart failure,
or revascularization
(percutaneous
coronary intervention
or coronary artery
bypass).
Participants or
relatives were
interviewed for
cardiovascular
events. All events
were reviewed at
each study site
using supporting
documentation,
verbal autopsies,
or medical
records; standard
deﬁnitions were
used.
4.89 (2.24) 100,475 (NL-IHRS)
107,863 (FC-IHRS)
352 NL-IHRS and FC-
IHRS
D’Agostino,
2001 [24]
No details provided. Coronary death or
myocardial infarction.
No details provided. No details
provided.
8,713 No details provided. Framingham
ACC/AHA, American College of Cardiology/American Heart Association; CHA2DS2VASc, Congestive Heart Failure, Hypertension, Age 75 Years, Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack or
Thromboembolism, Vascular Disease, Age 65 to 74 Years, Sex; CUORE, Continuous Ultraﬁltration for Congestive Heart Failure; ECG, electrocardiography; FC-IHRS, fasting cholesterol INTERHEART risk score; HDL, high-
density lipoprotein; ICD-10, International Classiﬁcation of Diseases, 10th revision; INTERHEART, Effect of Potentially Modiﬁable Risk Factors Associated With Myocardial Infarction in 52 Countries; IQR, interquartile
range; JNC VII, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; NL-IHRS, nonlaboratory INTERHEART risk score; PROCAM, Prospective
Cardiovascular Münster.
*Unless otherwise indicated.
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TABLE 3. Prediction properties of the prognostic models as reported in the reviewed reports
Study,
Year Ref. # Calibration Discrimination Classiﬁcation Measures
Polenz, 2015 [26] No details provided. C-statistic ¼ 0.62 (95% CI: 0.58e0.67) At a score of 6 points þ LR ¼ 3.45,
LR ¼ 0.78, sensitivity ¼ 28.6,
speciﬁcity ¼ 91.7 for the
occurrence of stroke or TIA; þLR ¼
3.35, LR ¼ 0.79, sensitivity ¼
27.3, speciﬁcity ¼ 91.9 for stroke,
TIA, and death.
Muñoz, 2014 [22] Framingham: overestimation; for people
at low and intermediate risk, the
relationship between expected and
observed was 1.31; for people at
high risk, the absolute difference
between the proportion of expected
and observed events was 17.4.
PROCAM: similar ﬁndings for all risk
groups; for people at low and
intermediate risk the absolute
difference between percentages of
expected and observed events was
<3%; poor calibration
(overestimation) for people at high
risk. PROCAM adjusted for sex (so
that can be used in men and women)
showed similar calibration
properties.
Framingham: AUC ¼ 0.6584 (95% CI:
0.6258e0.6907).
PROCAM: AUC ¼ 0.5819 (95% CI: 0.5238
e0.6385).
PROCAM adjusted for sex: AUC ¼ 0.7446
(95% CI: 0.7142e0.7740).
No details provided.
Gulayin, 2018 [20] They reported the b slope for
calibration. CUORE: y ¼ 1.012x 
0.0036. Framingham: y ¼ 1.0956x 
0.014. Globorisk: y ¼ 1.3718x 
0.0066. ACC/AHA pooled equation:
y ¼ 0.5103x þ 0.0095.
CUORE: C-statistic ¼ 0.751 and Harrell’s
C index ¼ 0.752.
Framingham: C-statistic ¼ 0.719 and
Harrell’s C index ¼ 0.722.
Globorisk: C-statistic ¼ 0.753 and
Harrell’s C index ¼ 0.736.
ACC/AHA pooled equation: C-statistic ¼
0.736 and Harrell’s C index ¼ 0.743.
CUORE: sensitivity ¼ 73% and
speciﬁcity ¼ 69%.
Framingham: sensitivity ¼ 81% and
speciﬁcity ¼ 51%.
Globorisk: sensitivity ¼ 75% and
speciﬁcity ¼ 60%.
ACC/AHA pooled equation:
sensitivity ¼ 75% and speciﬁcity ¼
58%.
Sandoya, 2009 [23] Hosmer-Lemeshow for men was 6.82
(p ¼ 0.56) and for women was 5.09
(p ¼ 0.64).
AUC for men was 0.76 (95% CI: 0.69
e0.82) and for women was 0.67
(95% CI: 0.56e0.78).
No details provided.
Acevedo, 2017 [19] No details provided. ACC/AHA pooled equation: AUC ¼ 0.78
(95% CI: 0.68e0.84).
Framingham: AUC ¼ 0.60 (95% CI: 0.52
e0.74).
Framingham Chileno: AUC ¼ 0.67 (95%
CI: 0.60e0.79).
No details provided.
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Jiménez-Corona, 2009 [21] The ratio of predicted/observed rates
using the ﬁrst equation (Framingham
by Wilson et al.) was 1.84 (95% CI:
1.15e2.53) in men and 1.55 (95% CI:
1.01e2.08) in women; the ratio
using the second equation
(Framingham by Anderson et al.
[27]) was 3.17 (95% CI: 1.67e4.68) in
men and 1.57 (95% CI: 1.67e2.17) in
women.
No details provided. No details provided.
Joseph, 2018 [25] Original NL-IHRS: slope ¼ 0.87
(0.77e0.98), intercept ¼ 4.43
(4.75 to 4.29); for the recalibrated
version these parameters were 1
(0.87e1.13) and 0 (0.48 to 0.48).
Original FC-IHRS: slope ¼ 1.11
(0.97e1.24), intercept ¼ 4.35
(4.49 to 4.21); for the recalibrated
version these parameters were 1
(0.88e1.12) and 0 (0.45 to 0.45).
Original NL-IHRS: C-statistic ¼ 0.72
(0.69e0.75); and so was for the
recalibrated version. Original FC-
IHRS: C-statistic ¼ 0.74 (0.71e0.77)
and so was for the recalibrated
version.
No details provided.
D’Agostino, 2001 [24] Best chi-square using the Puerto Rico
study’s means on the risk factors and
the Puerto Rico study’s CHD
incidence ¼ 7.2.
In Hispanic population, the best Cox
(applying the Cox model developed
on the Puerto Rico study’s data): C-
statistic ¼ 0.72.
No details provided.
AUC, area under the curve; CHD, coronary heart disease; CI, conﬁdence interval; LR, likelihood ratio; TIA, transient ischemic attack; other abbreviations as in Table 2.
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qualitative synthesis: none developed a prognostic model,
only 1 was conducted in the Caribbean [24], and many
have major limitations with regards to sample size and
analysis, for example, limited number of outcome events.
The Framingham and the American College of Cardiology/
American Heart Association Pooled Cohorts Equation were
the most studied tools. Calibration estimates changed
substantially from one population to another, with serious
overestimation in some cases, that is, individuals catego-
rized as high risk when they were not. Discrimination was
acceptable in many reports, particularly for the American
College of Cardiology/American Heart Association Pooled
Cohorts Equation. Based on these ﬁndings, and the het-
erogeneous health proﬁle of LAC populations, it is pre-
mature to strongly advocate for 1 prognostic model in
LAC.
Limitations at study level
Most studies analyzed few outcome events, which could
account for wide conﬁdence intervals, but most impor-
tantly for lack of power to make strong conclusions. Just
recently, new approaches for estimating sample size or
adequate number of events per predictors in the prognostic
models have been proposed [28,29]. Future cardiovascular
prognostic work could formally test these requirements.
Joseph et al. [25] conducted the work with the “largest”
outcome events per predictor ratio (ratio ¼ 16). None-
theless, and even though they had a model without labo-
ratory variables, the model had over 20 predictors, which
would make it troublesome to use in the ﬁeld because it
will require much information. In addition, some of the
predictors were about diet proﬁle [25], which could
require further knowledge about local foods, hence making
these questions difﬁcult to ascertain.
It seemed that the reviewed studies made a great effort to
conduct follow-up rounds and to accurately capture the
outcomes of interest; however, 1 study could not adjudicate
nonfatal outcomes even though the model being evaluated
needed them [19]. This highlights the necessity for national
health registries, at least of major events of noncommunicable
diseases. These could inform health authorities, as well as
researchers who will ultimately provide evidence to advise
public health and clinical practice.
Strengths and limitations at the review level
The research question and search strategy were deﬁned
following international guidelines for systematic reviews of
prognostic models [13,14]. The search terms were based on
previous systematic reviews and followed recommendations
for ﬁnding prognostic studies [9,10,30]. In addition, risk of
bias was formally assessed with a validated tool [16-18].
Nevertheless, this work is subject of several limitations. First,
given the results about heterogeneity and the low number of
reviewed reports, a quantitative summary (e.g., meta-
analysis) was not be conducted. Second, we could have
further reviewed gray reports, such as graduate programs
dissertations of LAC universities. Although this could have
retrieved more results, we doubt these would have been of
greater quality than the published works herein analyzed.
Therefore, we would have still not reached a strong recom-
mendation for (or against) a given prognostic model.
Other relevant publications
To summarize the strongest evidence on prognostic
research we focused on prospective studies. Nonetheless, it
seemed fair to also acknowledge other endeavors in LAC
that, despite following different study designs, have still
provided relevant evidence.
For example, Icaza et al. [31] adapted the Framingham
equation using population-based estimates on risk factors
and incidence of cardiovascular events based on national
registries in Chile. This work has informed clinical and
research practice in Chile. More recently, a population-
based cohort was initiated in Maule, Central Chile. The
MAUCO (Maule Cohort) study aims to enroll 10,000
people from 3 to 74 years old who will be followed for at
TABLE 4. Risk of bias assessment
Study, Year
Risk of Bias RoB Applicability Overall
Participants Predictors Outcome Analysis Participants Predictors Outcome
Risk
of Bias Applicability
Polenz, 2015 [26] Low Low Low High High Low Low High High
Muñoz, 2014 [22] Low Low Low High High Low Low High High
Gulayin, 2018 [20] Low Low Low High Low Low Low High Low
Sandoya, 2009 [23] Low Low Low High High Low Low High High
Acevedo, 2017 [19] Low Low High High High Low Low High High
Jiménez-Corona, 2009 [21] Low Low Low High Low Low Low High Low
Joseph, 2018 [25] Low Low Low High Low Low Low High Low
D’Agostino, 2001 [24] Low Low Low High Low Low Low High Low
PROBAST, Prediction model Risk Of Bias ASsessment Tool.
In the risk of bias assessment, low means low risk of bias, high means high risk of bias, and unclear when it was not possible to assess the risk of
bias. In the applicability section, high means high concern for applicability, low means low concern for applicability, and uncertain when it was not
possible to assess the applicability. Risk of bias conducted with the PROBAST tool [16-18].
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least 10 years, with outcome measurements focused on
cardiovascular diseases and cancer. The prospective design
of MAUCO offers a unique opportunity to develop local
prognostic models for the Chilean population [32]. Similar
efforts in Peru and Argentina may provide solid evidence
for these countries [33,34], though a regional approach
will still be missing.
The systematic search yielded 1 additional work from
Central America. This was a bold project that attempted to
generate a new prognostic model for myocardial infarction
using case-control data from Costa Rica [35]. Despite the
design limitations, they included a key item among their
predictors: socioeconomic status. This relevant health
determinant has been systematically excluded from many
prognostic models, though just recently it has been high-
lighted by a novel model developed for New Zealand [36].
LAC is a region with large socioeconomic inequalities, and
their effect on cardiovascular outcomes may be important.
Therefore, should a new cardiovascular prognostic model
be developed for LAC, a marker of socioeconomic status
should be at least tested among other potential predictors.
Although gray reports were beyond the scope of our
search, a master’s dissertation was also retrieved by our
search strategy; the outcome was coronary artery disease
and included 349 individuals in Brazil [37]. This work
included genetic predictors [37], which although relevant
and research on this ﬁeld should be fostered, it is perhaps
premature to have prognostic models with predictors that
are not widely available.
Finally, the Globorisk investigators developed cardiovas-
cular risk charts for 182 countries including those in LAC
[38,39]. Even though this was an example of global collabo-
ration and comprehensive research methods, the risk charts
were developed using risk prediction associations (e.g., hazard
ratios) fromcohortsmostly in theUnited States. Thismay limit
the applicability of thismodel to otherworld regions including
LAC, calling for updates to this and othermodelswith weights
(i.e., hazard estimates) retrieved from LAC studies.
Research gaps
This review identiﬁed a lack of cardiovascular prognostic
models developed in and for LAC populations, which
needs urgent attention. Research funders, along with
regional and local health agencies, should support new or
ongoing prospective cohort studies to address this gap.
This does not necessarily mean establishing a new multi-
country or region-wide cohort but supporting further
follow-up rounds of existing cohorts, particularly of
population-based cohorts. In addition, regional and local
health authorities could work to facilitate access to national
health/death registries for research purposes. This way,
large cross-sectional epidemiological studies and surveys
could access data on cardiovascular nonfatal and fatal
outcomes, in other words, entering the world of health big
data in LAC. In the meantime, cohort data pooling may be
a feasible solution.
Another relevant research gap observed by this review
is the dearth of studies from the Caribbean and Central
America regions. Besides a case-control study (Costa Rica)
[35] and a prospective cohort, the baseline assessment of
which was in the 1960s (Puerto Rico) [24], no additional
results were retrieved for these regions. This calls for in-
vestigators to strengthen local research capacity and to
generate, reuse, or update available cohorts in the Carib-
bean and Central America.
In terms of methods, this review found that 1 study
followed multiple imputation to account for missing data;
also, there were a low number of outcome events and some
predictors were categorized when they could have been
used as continuous variables [40,41]. These methodolog-
ical approaches could hide a lack of training or expertise in
validation (and development) of prognostic models.
Despite abundant methodological evidence (e.g., statistical
primers [42] and reviews [43-46]) on prognosis models,
these are mostly in English, which could be a limitation for
some researchers in LAC. In terms of capacity building,
existing training programs in epidemiology and related
ﬁelds should include prognostic research methods.
Reporting was also heterogeneous across studies. It
would be impossible for studies published before 2015 to
have adhered to the TRIPOD statement [47], but neither
did the post-2015 papers. This again calls for investigators
to improve prediction research capacity in LAC.
Implications for public health
Where poor-quality health care could be worse than any
health care [48], the health system should secure adequate
interventions to prevent diseases and complications. This
ranges from highly complex treatments to prevention
strategies. Among the latter, estimating the absolute risk of
an event might guide the allocation of treatment and pre-
ventive measures in favor of high-risk individuals. How-
ever, if prediction tools are not accurate enough, people
who do not need treatment would unnecessarily receive
medication and people who need it would not be identi-
ﬁed. Considering this systematic review, local and regional
health authorities, researchers, and practitioners should
understand the pitfalls of using available cardiovascular
prognostic models in LAC and procure the development,
comprehensive validation, or adequate recalibration of
available models.
Implications for clinical practice
Several international societies and clinical guidelines have
signaled the need to guide cardiovascular treatment and
other prevention interventions based on absolute risk for
which prognostic models are paramount [27,49-54]. In
particular, risk stratiﬁcation based on these models
contribute to allocation of health resources in a cost-
effective manner, allowing individuals with higher global
risk to receive adequate treatment and avoiding over-
treatment in individuals at low risk [27,49-54].
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In Chile, the tables of cardiovascular risk stratiﬁcation
adapted by Icaza et al. [31] were adopted by the Ministry of
Health and have been used in the public primary health
system since 2009 [54]. In 2013, Kunstmann et al. [55]
conducted a validation of the Chilean tables, conﬁrming
that they are useful in the prediction of coronary and ce-
rebrovascular events. Therefore, the Chilean tables
continue to be used to estimate the global risk of cardio-
vascular diseases at individual level in Chile [55].
The fact that no cardiovascular prognostic models have
been developed in LAC, and the fact that attempts to test
the accuracy of available prognostic models in LAC have
faced several limitations, puts LAC in a disadvantaged
position to successfully lessen the burden of cardiovascular
diseases. This review could not strongly recommend any
available prognostic model to be used across LAC settings.
Notwithstanding, acknowledging their limitations, weigh-
ing the pros and cons, and reaching an informed decision
with the patient, country-speciﬁc models could be used
after adequate recalibration.
CONCLUSIONS
No cardiovascular prognostic model has been developed in
or for the LAC region. The evaluation of available prog-
nostic models signals to several limitations, and their pre-
diction accuracy is questionable particularly regarding
calibration, albeit discrimination was acceptable in most
cases. Advancement of cardiovascular prognosis research
might contribute to improve the allocation of scarce re-
sources to people who need them the most, thus fostering
the prevention of cardiovascular diseases in this world re-
gion and to achieve this goal, appropriate cardiovascular
risk prediction is needed in the LAC region.
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